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Cholesterol represents a structurally and functionally important component of the
eukaryotic cell membrane, where it increases lipid order, affects permeability, and
influences the lateral mobility and conformation of membrane proteins. Several G
protein-coupled receptors have been shown to be affected by the cholesterol content
of the membrane, with functional impact on their ligand binding and signal transduction
characteristics. The effects of cholesterol can be mediated directly by specific molecular
interactions with the receptor and/or indirectly by altering the physical properties of the
membrane. This review focuses on the importance and differential effects of membrane
cholesterol on the activity of cholecystokinin (CCK) receptors. The type 1 CCK receptor
is quite sensitive to its cholesterol environment, while the type 2 CCK receptor is not.
The possible structural basis for this differential impact is explored and the implications of
pathological states, such as metabolic syndrome, in which membrane cholesterol may be
increased and CCK1R function may be abnormal are discussed. This is believed to have
substantial potential importance for the development of drugs targeting the CCK receptor.
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INTRODUCTION
Biological membranes consist of a variety of lipids and pro-
teins that establish diffusional boundaries for the cell and its
organelles. An important lipid component of the plasma mem-
brane is cholesterol that may be present in concentrations as high
as 20–40 mol%, which is known to have substantial impact on
the physical properties of the membrane and on the structure and
function of various intrinsic membrane proteins (Mouritsen and
Zuckermann, 2004).
The hydrophilic hydroxyl groups of the amphiphilic choles-
terol molecules are intercalated into the lipid bilayers, with one
cholesterol molecule spanning approximately half of the bilayer
(Mouritsen and Zuckermann, 2004). Cholesterol has the unique
ability to increase order in such membranes by organizing the
arrangement of the surrounding lipids, while maintaining flu-
idity and lateral diffusion within the membrane. A region of
the membrane in which cholesterol is absent typically exhibits
disorder and rapid lateral diffusion with randomly packed lipid
molecules (Miao et al., 2002; Mouritsen and Zuckermann, 2004).
Lowering the temperature can result in a transition from a liquid-
disordered phase toward a solid-ordered phase having slower
lateral diffusion and greater ordering of the lipid chains. The pres-
ence of cholesterol can also induce order in the liquid phase by
increasing the density of the packing of fatty acyl chains. This
is also identified as a liquid-ordered phase (Ipsen et al., 1987).
Abbreviations: CCK, cholecystokinin; cAMP, cyclic adenosine monophosphate;
CCM, cholesterol consensus motif; CRAC, cholesterol recognition/interaction
amino acid consensus; DAG, diacylglycerol; FRET, fluorescence resonance energy
transfer; GPCRs, guanine nucleotide-binding protein-coupled receptors; MβCD,
methyl-beta-cyclodextrin; IP3, inositol triphosphate.
Cholesterol can also affect the permeability function of the mem-
brane by changing its lateral density fluctuations and structural
heterogeneity and thereby regulating its “leakiness.” The effect of
cholesterol on lipid order also affects the thickness of the bilayer
(Ohvo-Rekila et al., 2002; Mouritsen and Zuckermann, 2004). In
the presence of low or absent cholesterol, sodium ions are able
to passively permeate the lipid bilayer, while such permeability is
inhibited in the presence of high (40%) cholesterol (Ohvo-Rekila
et al., 2002). Cholesterol can also bind and inhibit some solutes
such as ethanol, which become strongly adsorbed as a result of
density fluctuations and the heterogeneous composition of the
bilayer (Schroeder et al., 1996).
Cholesterol can also contribute to specialized microdomains
within the plasma membrane that are known as planar lipid rafts.
These are small, low-density regions in the outer leaflet of the
bilayer that are enriched in cholesterol and glycosphingolipids.
These structures have been identified based on their insolubil-
ity in non-ionic detergents at low temperature and their high
buoyancy in density gradients (Brown and Rose, 1992). These
planar structures may also give rise to caveolae, representing flask-
shaped invaginations that can ultimately form free intracellular
organelles (Cohen et al., 2004; Shaw, 2006). It is notable that lipid
rafts and caveolae can act as organizational platforms for elements
involved in signal transduction (Okamoto et al., 1998; Pike, 2003;
Cohen et al., 2004; Ostrom and Insel, 2004).
EFFECTS OF MEMBRANE CHOLESTEROL ON G
PROTEIN-COUPLED RECEPTORS (GPCRs)
Several GPCRs have been reported to be sensitive to the con-
centration of cholesterol in the membrane, with different effects
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observed for different receptors (Table 1). Cholesterol can affect
receptor conformation, thereby affecting its ligand binding and
signaling characteristics. It can affect lateral mobility within
the bilayer that is critical for G protein coupling. It can also
affect receptor trafficking and sequestration that contribute to
desensitization. However, currently there are no well-established
rules for which receptors might be influenced by cholesterol and
how these receptors might be affected. Two distinct groups of
mechanisms have been proposed: (A) direct binding of choles-
terol molecules to GPCR molecules, including the possibility of
interacting with specific sites or motifs (Albert et al., 1996; Li
and Papadopoulos, 1998; Paila et al., 2009) and/or (B) indirect
effects of the cholesterol by altering the physical properties of the
membrane in which the GPCRs reside (Lee, 2004; Mouritsen and
Zuckermann, 2004).
The effects of membrane cholesterol on rhodopsin, the
photoreceptor of the retinal rod cells, have been extensively
studied. Rhodopsin exists in various conformations known as
metarhodopsins. The equilibrium between these conformational
states is sensitive to the amount of membrane cholesterol present,
with increased cholesterol shifting the equilibrium toward the
inactive states of the receptor (Mitchell et al., 1990; Bennett
and Mitchell, 2008). The influence of membrane cholesterol
on rhodopsin function has been attributed to both direct and
indirect mechanisms. Spatial approximation between tryptophan
residues of rhodopsin and cholesterol has been demonstrated
using fluorescence resonance energy transfer (FRET), with an
estimation of one sterol molecule interacting with one rhodopsin
molecule (Albert et al., 1996). These observations have been sup-
ported by the crystal structure of metarhodopsin I that includes
a cholesterol molecule bound between the tryptophan residues
of transmembrane segment four of one protomer and trans-
membrane segments five, six, and seven of the other protomer
(Ruprecht et al., 2004). An indirect effect of cholesterol has also
been attributed to its effect on the partial free volume of themem-
brane. The conversion of metarhodopsin I to metarhodopsin II
involves an expansion of the protein in the plane of the lipid
bilayer (Attwood and Gutfreund, 1980), thereby occupying the
partial free volume of the surrounding bilayer. As membrane
cholesterol is increased, the formation of metarhodopsin II is
decreased by reducing the partial free volume in the membrane
(Niu et al., 2002).
Table 1 | List of GPCRs affected by membrane cholesterol.
GPCR Effect of membrane cholesterol References
β2-adrenergic Cholesterol improves stability of the receptor and facilitates its crystallization. It
also modulates isolation of the receptor from its signaling components in
liquid-ordered lipid nanodomains, and thereby affects signaling.
Ben-Arie et al., 1988; Hanson et al.,
2008; Pontier et al., 2008
Cannabinoid CB1R is dependent on cholesterol concentrated in lipid rafts for ligand binding and
signaling and the CRAC motif is responsible for its direct interaction with
membrane cholesterol.
Bari et al., 2005a,b; Oddi et al., 2011
Chemokine Cholesterol is essential for CXCR4 and 5 conformation and function. Nguyen and Taub, 2002a,b, 2003
Cholecystokinin Cholesterol interacts at specific sites in the transmembrane segments of the
CCK1R (CCKAR), and affects its ligand binding and signaling abilities. CCK2R
(CCKBR) is not affected.
Gimpl et al., 1997, 2002; Harikumar
et al., 2005b; Potter et al., 2012
Dopamine D1 receptors in renal cells can associate with caveolin-2 in caveolae, where they
activate adenylate cyclase.
Yu et al., 2004; Genedani et al., 2010
Galanin Membrane cholesterol supports the ligand binding process in a positively
co-operative manner.
Pang et al., 1999
Metabotropic
glutamate
Enrichment of cholesterol in Drosophila melanogaster photoreceptor cell
membranes induces receptor association with lipid rafts and shift to the high
affinity state.
Eroglu et al., 2003
Muscarinic Cholesterol promotes cooperativity in binding of antagonists to the M2 muscarinic
receptors.
Colozo et al., 2007
Neurokinin Monomeric neurokinin-1 receptors are localized in the lipid rafts and caveolae.
Cholesterol content is directly proportional to the signaling.
Monastyrskaya et al., 2005; Meyer
et al., 2006
Opioid Cholesterol present in lipid rafts and caveolae is important for agonist affinity,
where it affects G protein coupling.
Lagane et al., 2000; Xu et al., 2006;
Huang et al., 2007
Oxytocin Amount of cholesterol in the membrane is directly proportional to the ligand
binding affinity of the receptor.
Gimpl et al., 1997, 2002; Gimpl and
Fahrenholz, 2002
Serotonin Reduction in cholesterol compromises organization, ligand binding, and G protein
coupling at the 5HT1A and 5HT7A receptors.
Pucadyil and Chattopadhyay, 2004,
2005; Sjogren et al., 2006
Rhodopsin Elevated cholesterol inhibits the activation of rhodopsin receptor. Mitchell et al., 1990; Niu et al., 2002;
Bennett and Mitchell, 2008
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Similarly, cholesterol has been shown to be bound to the β2-
adrenergic receptor in its crystal structure (Hanson et al., 2008),
and this lipid has been shown to be necessary for ligand binding,
G protein interaction, and signal transduction at that receptor
(Ben-Arie et al., 1988). Two cholesterol molecules appear to be
bound to sites on transmembrane segments one, two, three, and
four of a β2-adrenergic receptor molecule (Hanson et al., 2008).
Other examples include the oxytocin receptor, where the
amount of cholesterol in the membrane is directly related to
the ligand binding affinity of the receptor (Gimpl et al., 1997,
2002; Gimpl and Fahrenholz, 2002) [43% decrease in membrane
cholesterol caused a sharp decline in ligand binding (Gimpl et al.,
1997)]. This has been shown to be a highly co-operative pro-
cess where more than six molecules of cholesterol can be bound
to one oxytocin receptor molecule (Gimpl et al., 2002). There is
clear structural specificity for this interaction, since only choles-
terol analogs that are structurally similar to cholesterol are able to
reproduce this effect on oxytocin receptor function (Gimpl et al.,
1997). Cholesterol is also believed to provide stability against
thermal and pH alterations, and to protect some receptors from
proteolytic degradation (Gimpl and Fahrenholz, 2002). Similarly,
in the case of the galanin-2 receptor, cholesterol affects ligand
binding process in a positively co-operative manner (Pang et al.,
1999). Only a limited number of cholesterol analogs are able to
exhibit similar effects to those of cholesterol, again supporting
structural specificity of this interaction (Pang et al., 1999). Other
examples of GPCRs affected by membrane cholesterol are listed
in Table 1.
Some interactions of membrane cholesterol with GPCRs have
been attributed to the presence of consensus motifs within
these receptors. Several proteins that are known to interact with
cholesterol have a characteristic amino acid sequence, termed
the cholesterol recognition/interaction amino acid consensus
(CRAC) motif, in their transmembrane segments. This is defined
by the pattern—L/V-(X)1–5-Y-(X)1–5-R/K-, in which (X)1–5
represents between one and five residues of any amino acid (Li
and Papadopoulos, 1998). This sequence is present in rhodopsin,
β2-adrenergic, serotonin1A, and cholecystokinin (CCK) recep-
tors (Jafurulla et al., 2011; Potter et al., 2012). Another con-
sensus motif, the strict-cholesterol consensus motif (CCM), was
described in transmembrane segments by Hanson et al. (2008),
and was later expanded by Adamian et al. (2011). This motif
[4.39–4.43 (R,K)] [4.50 (W,Y)] [2.45 (S)] [4.46 (I,V,L)] [2.41
(F,Y)] that incorporates the Ballesteros and Weinstein number-
ing system based on residue position relative to most conserved
residues within a given transmembrane segment (Ballesteros and
Weinstein, 1992), was recognized from the analysis of the 2.8 Å
structure of the human β2-adrenergic receptor and is present in
21% of the class A GPCRs (Hanson et al., 2008). A less-restrictive
variant of this motif is also found in 44% of class A GPCRs, where
the aromatic residue is absent at the position 2.41. The presence of
this motif, suggests that specific sterol binding may be important
to the structure and stability of receptors in this family.
CHOLECYSTOKININ (CCK) PEPTIDES AND PHYSIOLOGY
The GPCRs that are responsive to the gastrointestinal and brain
peptide, CCK, are the major focus of this review, with one of the
CCK receptors affected by cholesterol and the other unaffected.
CCK is a polypeptide hormone synthesized in the I-cells of the
small intestine (Rehfeld, 1978) that is released in response to pro-
tein and fat in the lumen that plays an important role in nutrient
homeostasis. CCK was identified based on its ability to stimulate
gallbladder contraction, and it was also eventually recognized as
being identical to pancreozymin, a hormone that stimulates pan-
creatic exocrine secretion (Harper and Raper, 1943). CCK also
contributes to post-cibal satiety (Kissileff et al., 1981; Smith and
Gibbs, 1985; Beglinger et al., 2001), which is a critically impor-
tant role that could provide the basis of a treatment of obesity.
This hormone is also one of the most abundant neuropeptides
present in the brain (Miller et al., 1984), and it has been shown
to have effects on enteric smooth muscle and nerves at various
locations in the peripheral and central nervous system. It also
has been described to have direct natriuretic effects on the kid-
ney, and to decrease renal excretion of calcium and magnesium
(Duggan et al., 1988; Ladines et al., 2001). CCK is present as a
variety of different length peptides that are produced from a single
115-residue preprohormone precursor, all sharing their carboxyl-
terminal sequence. These range from 58, 39, 33, and 8 residues,
with each containing a sulfated tyrosine residue seven residues
from the carboxyl terminus, as well as amidation of the carboxyl-
terminal phenylalanine residue (Eysselein et al., 1990; Rehfeld
et al., 2001; Miller and Gao, 2008).
CCK RECEPTOR STRUCTURE AND FUNCTION
CCK exerts its physiological functions through the activation of
two structurally-related class A GPCRs identified as CCK receptor
type 1 (CCK1R) and CCK receptor type 2 (CCK2R) (also known
as CCKAR and CCKBR, respectively, related to their prominent
presence in “alimentary tract” and “brain”) (Dufresne et al.,
2006). CCK2R also binds gastrin, another structurally-related
polypeptide hormone produced in the gastric antrum (Kopin
et al., 1992). In contrast, CCK1R binds gastrin at a very low affin-
ity (by 500-fold). Both these receptors are highly homologous and
approximately 50% identical, particularly in the transmembrane
regions where they are 70% identical (Miller and Gao, 2008).
Although both types of CCK receptors bind and are activated by
CCK and gastrin peptides, the molecular basis for peptide bind-
ing to these receptors appears to be distinct. The CCK1R requires
the carboxyl-terminal CCK heptapeptide-amide that includes the
sulfated tyrosine for high affinity binding and biological activity,
whereas the CCK2R requires only the carboxyl-terminal tetrapep-
tide amide that is shared between all CCK and gastrin receptors
(Miller and Gao, 2008). The activation of the CCK1R by CCK
elicits a broad variety of important physiological functions, such
as stimulation of gallbladder contraction and pancreatic exocrine
secretion, delay of gastric emptying, relaxation of the sphincter
of Oddi, inhibition of gastric acid secretion, and induction of
post-cibal satiety (Kerstens et al., 1985; Schmitz et al., 2001). The
CCK1R is localized in the human gastric mucosa within D cells
(Schmitz et al., 2001) and muscularis propria of human gastric
antrum, fundus, and pylorus (Reubi et al., 1997). CCK2R is local-
ized mainly in brain and is also present in the gastric oxyntic
mucosa, some enteric smooth muscle, and the kidneys (Noble
and Roques, 1999; Von Schrenck et al., 2000). In addition to
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stimulation of gastric acid secretion, CCK2R also plays a role in
anxiety and nociception (Noble and Roques, 1999; Noble, 2007).
The CCK receptors belong to the class A group of GPCRs
[see review of CCK receptor structure and pharmacology (Miller
and Gao, 2008)]. They share the typical signature sequences of
this family, including E/DRY at the intracellular side of trans-
membrane segment three and NPxxY at the intracellular side
of transmembrane segment seven. Both receptors are glycosy-
lated, possess the conserved disulfide bond between extracellular
loops one and two (CCK1R also has an extra disulfide bond
within the amino-terminal extracellular domain), and include
multiple sites for serine and threonine phosphorylation in intra-
cellular loop three and in the carboxyl-terminal tail. The function
of phosphorylation is to desensitize the receptor, interfering
with its coupling to G proteins (Rao et al., 1997). These recep-
tors also have cysteine residues representing sites of palmitoy-
lation in the intracellular carboxyl-terminal tail, which help to
attach an eighth helical segment to the cytosolic face of the
bilayer.
A broad range of approaches, including ligand binding and
signaling of chimeric and site-specific mutants (Kopin et al.,
1995; Miller and Lybrand, 2002), photoaffinity labeling (Ding
et al., 2001; Dong et al., 2005, 2007) and fluorescence-based tech-
niques (Harikumar et al., 2004, 2005a, 2006; Harikumar and
Miller, 2005) have provided important information regarding the
molecular basis of CCK binding to these receptors. Information
from these studies has shown that the determinants for CCK
binding to the CCK1R are distributed throughout the extracel-
lular loop and amino-terminal tail regions, but not within the
predicted transmembrane domain bundle (Miller and Lybrand,
2002; Harikumar et al., 2004). However, a possible difference for
CCK binding to these two receptors relates to the position of the
carboxyl-terminal end of the peptide. This portion of CCK resides
at the surface of the lipid bilayer adjacent to transmembrane
segment one for the CCK1R, as directly demonstrated by site-
selective photoaffinity labeling (Harikumar et al., 2004), while
it may dip into the helical bundle for the CCK2R, although the
latter is based on less definitive data coming from site-directed
mutagenesis (Harikumar et al., 2006).
Table 2 shows differences in microenvironment-dependent
spectral properties of fluorescent CCK ligands docked to CCK1
or CCK2 receptors, supporting the suggested differential binding
of the ligands to these two receptors.
Various selective and potent non-natural ligands for the
CCK receptor have been developed [see reviews (Herranz, 2003;
Kalindjian and McDonald, 2007)]. The most extensively stud-
ied in regard to mechanism of binding to CCK receptors is
the group of benzodiazepine compounds (Aquino et al., 1996;
Darrow et al., 1998; Gao et al., 2008; Cawston et al., 2012). Minor
chemical modifications of these compounds have been shown to
change receptor subtype selectivity and biological responsiveness
(Aquino et al., 1996; Gao et al., 2008; Miller and Gao, 2008). It
is now clear, based on receptor mutagenesis, photoaffinity label-
ing, and pharmacological manipulations, that these ligands bind
to an allosteric site within the intramembranous helical bun-
dle that is distinct from the orthosteric CCK peptide-binding
site of the CCK1R (Kopin et al., 1994; Hadac et al., 2006; Gao
et al., 2008). In fact, using two specific benzodiazepine antagonist
ligands, it has been shown that transmembrane segments six and
seven [residues 6.51, 6.52, and 7.39 (Ballesteros and Weinstein,
1992)] are most important for binding the CCK1R-selective lig-
and, whereas residues of transmembrane segments two and seven
Table 2 | Summary of studies demonstrating the differential binding of fluorescent CCK probes to CCK1 and CCK2 receptors.
CCK1R CCK2R
• CCK-8-based probe had shorter half-life and lower anisotropy
(more mobility) in the active than inactive conformation of the
receptor.
• CCK-8-based probe had shorter half-life and lower anisotropy (more
mobility) in the active than inactive conformation of the receptor.
However, when bound, absolute values for lifetime and anisotropy were
lower (more exposure to the aqueous milieu) than those in the CCK1R.
• CCK-4-based probe was not tolerated. • CCK-4-based probe was tolerated. There was less quenching of this probe
(reduced exposure to aqueous milieu) than the CCK-8-based probe.
• Fluorophore corresponding to the amino terminus of the CCK
(position 24) was more accessible to aqueous milieu in the active
than inactive conformations of the receptor.
• Flourophore corresponding to the amino terminus of CCK (position 24)
behaved in a similar manner to CCK1R.
• Fluorophore corresponding to the mid-region of the peptide
(position 29) was least accessible to the aqueous milieu and
unaltered by changes between active and inactive conformations
of the receptor.
• Fluorophore corresponding to the mid-region of the peptide (position 29)
behaved in a similar manner to the CCK1R.
• Fluorophore corresponding to the carboxyl terminus of the peptide
(position 33) was more accessible to aqueous milieu in the active
conformation of the receptor.
• The behavior of the fluorophore corresponding to the carboxyl terminus of
the peptide (position 33) was less accessible to the aqueous milieu in the
active conformation the receptor.
Top, CCK analogs with a fluorescent alexa indicator at the amino terminus of a CCK-8 analog and a CCK-4 analog were used to examine the microenvironment of
the fluorophore as docked to CCK1 or CCK2 receptors (Harikumar et al., 2005a).
Bottom, CCK analogswith a fluorescent aladan indicator at the amino terminus, mid-region, or carboxyl-terminus of CCK were used to examine themicroenvironment
of the fluorophore as docked to CCK1 or CCK2 receptors. Fluorescence quenching, anisotropy and red edge excitation shifts were examined (Harikumar et al., 2006).
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(2.61 and 7.39) are most important for binding the CCK2R
selective ligand (Cawston et al., 2012).
EFFECTS OF MEMBRANE CHOLESTEROL ON CCK RECEPTOR
FUNCTION
The ability of CCK to induce gallbladder contraction has been
shown to be reduced in individuals with cholesterol gallstones
(Fridhandler et al., 1983; Lamorte et al., 1985; Behar et al., 1989;
Chen et al., 1997; Amaral et al., 2001; Kano et al., 2002). Initially,
it was shown that high cholesterol diet (1–1.2%) induced choles-
terol stone formation in the gallbladders of animals like prairie
dogs and ground squirrels (Fridhandler et al., 1983). Gallbladder
muscle contraction in these models was impaired in response
to CCK, but it was also impaired in response to acetylcholine
and the non-hormonal stimulant potassium (Lamorte et al.,
1985). Studies using muscle strips from human gallbladders with
cholesterol gallstones have also demonstrated reduced contrac-
tility in response to CCK (Behar et al., 1989). Similar effects
were observed when studying in vivo gallbladder contraction in
response to CCK in patients with gallbladder disease (Amaral
et al., 2001). More specifically, using isolated human gallblad-
der smooth muscle strips and single muscle cells, it has been
shown that specimens with cholesterol stones exhibit lower cAMP
responses compared with those in gallbladders with pigment
stones. Hence, it was suggested that the muscle defect responsi-
ble for this impairment was at the level of the plasma membrane
(Chen et al., 1997).
Indeed the plasma membrane can incorporate excessive
amounts of cholesterol in the presence of cholesterol-
rich environment by diffusion (Nichols and Pagano, 1981).
Studies measuring the amount of membrane-bound esterified
[3H]cholesterol in the presence of excessive amounts of unes-
terified [3H]cholesterol, had already confirmed the existence
of this phenomenon in cell types such as erythrocytes (Lange
and D’Alessandro, 1977) and rat arterial smooth muscle cells
(Slotte and Lundberg, 1983). It was suggested from these
observations that membrane cholesterol was a key factor in
causing the gallbladder muscle impairment. This was confirmed
in a study by Yu et al. (1996), in which they measured the
cholesterol content of isolated single muscle cells and plasma
membranes from gallbladder muscles from prairie dogs, finding
an association of elevated cholesterol with reduced muscle
contractility. It was reported that after feeding a high choles-
terol (1.2%) diet, cholesterol content, and the molar ratio of
cholesterol/phospholipid in plasma membranes of gallbladder
muscle increased by 90%, with a parallel decrease in muscle
contractility by 58% in response to CCK. Similar changes were
observed when normal gallbladder muscle cells were incubated
with cholesterol-rich liposomes, an effect which was reversed
upon incubation with cholesterol-free liposomes (Yu et al.,
1996). These observations were also confirmed in human gall-
bladder muscle from patients with cholesterol gallstones (Chen
et al., 1999; Xiao et al., 1999), where the membrane cholesterol
content and cholesterol/phospholipid ratio was significantly
higher in gallbladders with cholesterol stones than in those
with pigment stones. Membrane anisotropy was also higher in
gallbladders from patients with pigment gallstones, reflecting
lower membrane fluidity in gallbladders from patients with
cholesterol gallstones (Chen et al., 1999).
A report studying CCK signaling in isolated single muscle
cells from human gallbladders with cholesterol gallstones demon-
strated that the production of IP3 and diacylglycerol (DAG) was
reduced when compared with gallbladders from patients with
pigment gallstones (by 80–90% and 78%, respectively) (Yu et al.,
1995). However, this effect could be circumvented by stimulating
the cells with agents acting directly on G proteins. These results
suggested that the defect was proximal to the G protein, at the
level of the CCK receptor or its coupling with the G protein
(Yu et al., 1995). An illustrative clinical report was published in
1995 that described a patient with morbid obesity and choles-
terol gallstone disease in whom the CCK1R was misspliced to
yield a non-functional variant missing its third exon (Miller et al.,
1995). The frequency of such events is likely extremely low based
on another study by the same group (Nardone et al., 1995), in
which full length sequencing of the cDNA encoding the CCK1R
was shown to be entirely normal in 12 patients with cholesterol
gallstones undergoing cholecystectomy (Nardone et al., 1995).
Despite normal molecular structure, the function of CCK recep-
tors in patients with cholesterol gallstone disease has been directly
shown to be abnormal (Xiao et al., 1999). Of particular inter-
est, the apparent affinity of binding was higher than normal,
while the ability of this hormone to stimulate a signaling response
was decreased. These abnormalities were reversed after extrac-
tion of excess cholesterol from the membrane by incubation with
cholesterol-free liposomes (Xiao et al., 1999).
Indeed the impact of membrane cholesterol on this recep-
tor was further explored in manipulatable model systems in
2005 (Harikumar et al., 2005b). This study included exten-
sive analyses of the CCK1R function in lipid-modified environ-
ments and showed that normal CCK1R function is dependent
on the content of cholesterol in the membrane. In order to
monitor the changes in conformation of the CCK1R in the
presence of various levels of cholesterol, the study used two dif-
ferent fluorescence-based approaches by measuring anisotropy
and lifetimes of a fluorescent full agonist ligand, which shows a
decrease in both of these parameters when occupying a recep-
tor in active conformation (Harikumar et al., 2002). Cholesterol
depletion from CCK1R-bearing cells using chemical (MβCD
chelator) ormetabolic (lipoprotein deficient serum supplemented
with hydroxymethylglutaryl-CoA reductase inhibitor) methods
increased the movement of the label as reflected by decreased
anisotropy and reduced lifetime, whereas cholesterol enrichment
had the opposite effect. The fluorescence changes in the pres-
ence of increased cholesterol were similar to those observed in
the presence of a non-hydrolyzable GTP analog which is known
to shift the receptor into an inactive, G protein-uncoupled state
(Harikumar et al., 2002).
The changes in the conformation of the CCK1R in response
to varying amounts of membrane cholesterol are reflected in
its ligand binding characteristics and in its biological activity
(Harikumar et al., 2005b). Cholesterol depletion was shown to be
associated with a reduction in CCK binding affinity, while aug-
mentation of membrane cholesterol content actually increased
CCK binding affinity. However, the higher binding in the presence
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of increased cholesterol was non-productive, resulting in lower
biological responsiveness, like the membranes depleted in choles-
terol. Notably, the defective intracellular calcium responses to
CCK after cholesterol depletion were reversed upon cholesterol
repletion. These observations support a defective coupling of
the CCK receptor to its G protein in the presence of abnormal
membrane cholesterol content (Chen et al., 1997; Xiao et al.,
1999).
Other properties such as clathrin-mediated receptor inter-
nalization after agonist occupation, and receptor recycling were
unaffected by modulation of the membrane cholesterol content,
although these regulatory processes have been described to be
abnormal after modification of membrane sphingolipid content.
This indicates that two different lipid components by themselves
or in combination with other lipid components of the plasma
membrane probably induce different conformational changes to
the CCK1R which can lead to either defective G protein cou-
pling (in case of cholesterol), or disruption in the internalization
and recycling pathways (sphingolipid) of the CCK1R. These are
reflected by the differences in the observed effects on binding,
signaling, and receptor internalization (Harikumar et al., 2005b).
However, it is still unclear whether these effects of modification
of cholesterol and sphingolipids reflect events occurring in the
bulk phase of the plasma membrane or within rafts. Nevertheless,
these insights have added a new dimension to our understanding
of CCK receptor biology.
POSSIBLE STRUCTURAL BASIS FOR THE DIFFERENTIAL
SENSITIVITY OF CCK RECEPTORS TO CHOLESTEROL
In contrast, the other subtype of CCK receptor, the CCK2R,
is not sensitive to alterations in membrane cholesterol (Potter
et al., 2012). As noted earlier, these receptors are highly homol-
ogous and, in fact, share all of the predicted cholesterol binding
motifs (Figure 1). The key structural determinant for cholesterol
sensitivity appears to reside in the third exon of the CCK1R
which encodes most of the transmembrane segment three and
four, including one CRAC motif and one CCM motif (Potter
et al., 2012). It should be noted that the CCK1R and CCK2R
do not contain the entire four-component strict-CCM, but a less
restrictive CCM motif that is shared by 44% of human class
A GPCRs (Hanson et al., 2008). This is due to the absence of
an aromatic residue at 2.41. The relevant contributors to this
effect were further studied with site-directed mutants (Potter
et al., 2012). This suggested that three residues, Y140 (Y3.51),
which is a part of the CRAC motif (Li and Papadopoulos, 1998)
in transmembrane segment three, W166 (W4.50), which is a
part of the CCM (Hanson et al., 2008) in transmembrane seg-
ment four and Y237 (Y5.66), which is part of the CRAC motif
in transmembrane segment five, are important for the choles-
terol sensitivity of the CCK1R. It is noteworthy that mutation
of each of the three residues has negative effects on either CCK
binding or CCK-induced signaling. Mutation of Y140 to alanine
leads to reduced signaling but increased CCK binding affinity
and is insensitive to reduction in membrane cholesterol lev-
els. On the other hand, mutation of W166 to alanine leads to
decreased CCK binding and signaling ability of the CCK1R,
with a further reduction in signaling upon depleting membrane
cholesterol. The Y237A mutant displays no change in signaling,
but reduced CCK binding affinity, whereas cholesterol reduction
results in the reduction of both parameters. Corresponding sin-
gle residue mutations (Y153A, W179A, Y246A) within the CRAC
and the CCM motifs of the CCK2R did not modify receptor
function.
It is remarkable that mutation of only Y140 residue within
the CRACmotif within transmembrane segment three resulted in
loss of cholesterol sensitivity of the CCK1R (Potter et al., 2012).
This implies a defective conformation of the receptor, particularly
because the mutation alters the conserved (D/E) 3.49-R3.50-
Y3.51 motif, and thus its ability to mediate the differential effects
of cholesterol in the two structurally related receptors is compro-
mised. However, studies with other class A GPCRs have shown
that the mutation of Y3.51 of the D/ERY motif does not affect
the ligand binding affinity or receptor trafficking, and has no
or marginal effects on receptor signaling (Ohyama et al., 2002;
Gaborik et al., 2003; Proulx et al., 2008). So, it appears that
probably this residue is specifically responsible for the differential
cholesterol sensitivity observed between the CCK receptors. This
implies that the transmembrane segment three CRAC cholesterol
binding motif could be responsible for the cholesterol sensitivity
of the CCK1R, because the transmembrane segment four CCM
(W166) and transmembrane segment five CRAC (Y237) mutants
are still sensitive to cholesterol. However, the transmembrane
segment three CRAC cholesterol-binding motif is essentially the
same in both the CCK receptors, differing only in the presence of
lysine in CCK1R and an arginine in the CCK2R. Both the residues
which are a part of the consensus motif have similar properties.
FIGURE 1 | Schematic representation of the alignment of structural segments of the CCK1R and CCK2R. The CCM (red) and the CRAC (violet) are
highlighted within the transmembrane segments (rectangles) and intracellular loops (black line) of the CCK1R (top, blue) and CCK2R (bottom, gray).
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While the sequence surrounding the motif is largely similar, they
do exhibit minor differences between the two receptors that could
contribute to the observed difference in the cholesterol sensitivity.
These observations show that the presence of a CRAC or/and
CCM motif do not necessarily mean that the receptor is sensi-
tive to cholesterol. At least in the case of the CCK receptors, it
appears that the subtype specific conformational changes are con-
ferred by the differences in direct interaction of the membrane
cholesterol with the two receptors. It has been shown in the case
of the human cannabinoid receptors (CBR), that the type 1 CBR
(CB1R) is affected by manipulations in the membrane cholesterol
content, in a way similar to the CCK1R exhibiting defective ligand
binding and signaling, as well as its localization to membrane rafts
(Bari et al., 2005a,b). On the other hand, similar to CCK2R, the
type 2 CBR (CB2R) does not share this sensitivity to membrane
cholesterol (Bari et al., 2005a,b). In fact it was found that CB1R
possesses a CRAC motif in transmembrane segment seven that
differs by one residue from that in the CB2R, and the correspond-
ing mutation rendered CB1R insensitive to membrane cholesterol
similar to CB2R (Oddi et al., 2011). This explains that choles-
terol binding motifs outside of the CCM can have a significant
influence on receptor signaling and trafficking.
In addition to this, other possibilities for the differential sen-
sitivity of CCK receptors may be related to the indirect impact of
the cholesterol on the processes like mechanism of ligand bind-
ing or receptor trafficking. As mentioned earlier, the CCK1R
and the CCK2R bind the same CCK peptide ligand differently
(Silvente-Poirot and Wank, 1996; Dong et al., 2005; Harikumar
et al., 2005a, 2006). The peptide ligand binds to extracellular
loops and the amino-terminal tail of the CCK1R, whereas in the
CCK2R, the carboxyl-terminal end of the peptide ligand may dip
into the helical bundle (Harikumar et al., 2005a, 2006). It can
be postulated that in the case of CCK2R the peptide binding
within the helical bundle could potentially stabilize it and conse-
quently the intracellular regions as well, and prevent the negative
impact of changing membrane cholesterol. On the other hand,
the impact of membrane cholesterol cannot be overcome in the
case of the CCK1R because the conformational changes affecting
the extracellular regions binding the ligand are very different to
that conferred to the part of the receptor within the lipid bilayer.
So, these differential changes on the domains of the receptors
which are physically further away,may dictate the observed effects
of cholesterol sensitivity in the CCK1R.
Other processes occurring post ligand binding can also be
affected by changes in membrane cholesterol, which can con-
tribute to the observed effects. In the case of CCK1R, the recep-
tor has been described to occupy a unique plasma membrane
compartment after CCK stimulation of rat pancreatic acinar cells
(Roettger et al., 1995). This was called as a site of “insulation”
that is comparatively devoid of G proteins, in which the lateral
mobility of the CCK receptor is markedly reduced as another
highly specialized cellularmechanism of desensitization (Roettger
et al., 1999). Accordingly, it can be postulated that the membrane
cholesterol can cause similar changes to the CCK1R, however,
there is no information yet about the existence of a similar mech-
anism for CCK2R. Also, whether the CCK receptors are located
in the lipid rafts, and if the cholesterol modulation effects are
exclusive to these regions remains to be investigated.
CONCLUSION AND THERAPEUTIC PERSPECTIVES
It is clear that lipid-protein interactions, especially cholesterol-
receptor interactions, involved in the function of GPCRs can be
extremely important. More specifically, this review has focused on
the role of cholesterol in the function of the CCK1R, an impor-
tant receptor likely to be involved in pathologic states such as
obesity and metabolic syndrome. A better understanding of the
mechanisms of appetite regulation that contribute to the devel-
opment of obesity could provide insights into the prevention
and more effective treatment of this disorder. The gastrointesti-
nal hormones like CCK play important roles in servomechanisms
involved in regulating nutritional homeostasis. The observations
showing that elevated membrane cholesterol reduce the effec-
tiveness of stimulus-activity coupling activated by CCK action
at the CCK1R provide vital information regarding the patho-
logical phenomenon associated with CCK receptor dysfunction.
It is essential and would be very interesting to study the mem-
brane environment of the CCK1R receptor in obese patients,
in order to verify these observations in humans. Additionally, it
would be very exciting to study whether the mutations affecting
the cholesterol sensitivity might also be present in these patients.
Overall, the observations so far may suggest that elevated levels
of membrane cholesterol described in cholesterol gallstone dis-
ease and metabolic syndrome could reduce hormone-stimulated
signaling and, thereby, reduce the feedback inhibition of food
consumption that is an essential servomechanism. If this is proven
true in patients, the CCK1R can become the target for future
development of positive allosteric modulators that could “recal-
ibrate,” and consequently “normalize” this important regulatory
mechanism.
ACKNOWLEDGMENTS
We thank Dr. K. G. Harikumar for critical input on the
manuscript and insightful discussions. This work was supported
by a grant from the National Institutes of Health (DK32878).
REFERENCES
Adamian, L., Naveed, H., and Liang,
J. (2011). Lipid-binding surfaces of
membrane proteins: evidence from
evolutionary and structural anal-
ysis. Biochim. Biophys. Acta 1808,
1092–1102.
Albert, A. D., Young, J. E., and Yeagle,
P. L. (1996). Rhodopsin-cholesterol
interactions in bovine rod outer
segment disk membranes. Biochim.
Biophys. Acta 1285, 47–55.
Amaral, J., Xiao, Z. L., Chen, Q.,
Yu, P., Biancani, P., and Behar,
J. (2001). Gallbladder muscle dys-
function in patients with chronic
acalculous disease. Gastroenterology
120, 506–511.
Aquino, C. J., Armour, D. R., Berman,
J. M., Birkemo, L. S., Carr, R.
A., Croom, D. K., et al. (1996).
Discovery of 1, 5-benzodiazepines
with peripheral cholecystokinin
(CCK-A) receptor agonist activity.
1. Optimization of the ago-
nist “trigger”. J. Med. Chem. 39,
562–569.
Attwood, P. V., and Gutfreund,
H. (1980). The application of
pressure relaxation to the study
of the equilibrium between
metarhodopsin I and II from
bovine retinas. FEBS Lett. 119,
323–326.
Ballesteros, J. A., and Weinstein, H.
(1992). Analysis and refinement of
criteria for predicting the struc-
ture and relative orientations of
transmembranal helical domains.
Biophys. J. 62, 107–109.
www.frontiersin.org October 2012 | Volume 3 | Article 123 | 7
Desai and Miller Cholesterol impact on cholecystokinin action
Bari, M., Battista, N., Fezza, F., Finazzi-
Agro, A., and Maccarrone, M.
(2005a). Lipid rafts control signal-
ing of type-1 cannabinoid receptors
in neuronal cells. Implications for
anandamide-induced apoptosis.
J. Biol. Chem. 280, 12212–12220.
Bari, M., Paradisi, A., Pasquariello,
N., and Maccarrone, M. (2005b).
Cholesterol-dependent modulation
of type 1 cannabinoid receptors in
nerve cells. J. Neurosci. Res. 81,
275–283.
Beglinger, C., Degen, L., Matzinger, D.,
D’Amato, M., and Drewe, J. (2001).
Loxiglumide, a CCK-A receptor
antagonist, stimulates calorie intake
and hunger feelings in humans.
Am. J. Physiol. Regul. Integr. Comp.
Physiol. 280, R1149–R1154.
Behar, J., Lee, K. Y., Thompson, W. R.,
and Biancani, P. (1989). Gallbladder
contraction in patients with pig-
ment and cholesterol stones.
Gastroenterology 97, 1479–1484.
Ben-Arie, N., Gileadi, C., and
Schramm, M. (1988). Interaction
of the beta-adrenergic receptor
with Gs following delipidation.
Specific lipid requirements for Gs
activation and GTPase function.
Eur. J. Biochem. 176, 649–654.
Bennett, M. P., and Mitchell, D. C.
(2008). Regulation of membrane
proteins by dietary lipids: effects
of cholesterol and docosahex-
aenoic acid acyl chain-containing
phospholipids on rhodopsin sta-
bility and function. Biophys. J. 95,
1206–1216.
Brown, D. A., and Rose, J. K. (1992).
Sorting of GPI-anchored proteins to
glycolipid-enriched membrane sub-
domains during transport to the
apical cell surface. Cell 68, 533–544.
Cawston, E. E., Lam, P. C., Harikumar,
K. G., Dong, M., Ball, A. M.,
Augustine, M. L., et al. (2012).
Molecular basis for binding
and subtype selectivity of 1, 4-
benzodiazepine antagonist ligands
of the cholecystokinin receptor.
J. Biol. Chem. 287, 18618–18635.
Chen, Q., Amaral, J., Biancani, P., and
Behar, J. (1999). Excess membrane
cholesterol alters human gallblad-
der muscle contractility and mem-
brane fluidity. Gastroenterology 116,
678–685.
Chen, Q., Amaral, J., Oh, S., Biancani,
P., and Behar, J. (1997). Gallbladder
relaxation in patients with pig-
ment and cholesterol stones.
Gastroenterology 113, 930–937.
Cohen, A. W., Hnasko, R., Schubert,
W., and Lisanti, M. P. (2004).
Role of caveolae and caveolins in
health and disease. Physiol. Rev. 84,
1341–1379.
Colozo, A. T., Park, P. S., Sum,
C. S., Pisterzi, L. F., and Wells,
J. W. (2007). Cholesterol as a
determinant of cooperativity in
the M2 muscarinic cholinergic
receptor. Biochem. Pharmacol. 74,
236–255.
Darrow, J. W., Hadac, E. M., Miller,
L. J., and Sugg, E. E. (1998).
Structurally similar small molecule
photoaffinity CCK-A agonists
and antagonists as novel tools for
directly probing 7TM receptors-
ligand interactions. Bioorg. Med.
Chem. Lett. 8, 3127–3132.
Ding, X. Q., Dolu, V., Hadac, E.
M., Holicky, E. L., Pinon, D.
I., Lybrand, T. P., et al. (2001).
Refinement of the structure of the
ligand-occupied cholecystokinin
receptor using a photolabile amino-
terminal probe. J. Biol. Chem. 276,
4236–4244.
Dong, M., Ding, X. Q., Thomas, S.
E., Gao, F., Lam, P. C., Abagyan,
R., et al. (2007). Role of lysine187
within the second extracellular loop
of the type A cholecystokinin recep-
tor in agonist-induced activation.
Use of complementary charge-
reversal mutagenesis to define a
functionally important interdo-
main interaction. Biochemistry 46,
4522–4531.
Dong, M., Liu, G., Pinon, D. I., and
Miller, L. J. (2005). Differential
docking of high-affinity peptide lig-
ands to type A and B cholecys-
tokinin receptors demonstrated by
photoaffinity labeling. Biochemistry
44, 6693–6700.
Dufresne, M., Seva, C., and Fourmy, D.
(2006). Cholecystokinin and gastrin
receptors. Physiol. Rev. 86, 805–847.
Duggan, K. A., Hams, G., and
Macdonald, G. J. (1988). Modi-
fication of renal and tissue cation
transport by cholecystokinin
octapeptide in the rabbit. J. Physiol.
397, 527–538.
Eroglu, C., Brugger, B., Wieland, F.,
and Sinning, I. (2003). Glutamate-
binding affinity of Drosophila
metabotropic glutamate receptor is
modulated by association with lipid
rafts. Proc. Natl. Acad. Sci. U.S.A.
100, 10219–10224.
Eysselein, V. E., Eberlein, G. A.,
Hesse, W. H., Schaeffer, M.,
Grandt, D., Williams, R., et al.
(1990). Molecular variants of
cholecystokinin after endoge-
nous stimulation in humans: a
time study. Am. J. Physiol. 258,
G951–G957.
Fridhandler, T. M., Davison, J. S., and
Shaffer, E. A. (1983). Defective gall-
bladder contractility in the ground
squirrel and prairie dog during
the early stages of cholesterol gall-
stone formation. Gastroenterology
85, 830–836.
Gaborik, Z., Jagadeesh, G., Zhang, M.,
Spat, A., Catt, K. J., and Hunyady,
L. (2003). The role of a con-
served region of the second intra-
cellular loop in AT1 angiotensin
receptor activation and signaling.
Endocrinology 144, 2220–2228.
Gao, F., Sexton, P. M., Christopoulos,
A., and Miller, L. J. (2008).
Benzodiazepine ligands can act
as allosteric modulators of the Type
1 cholecystokinin receptor. Bioorg.
Med. Chem. Lett. 18, 4401–4404.
Genedani, S., Carone, C., Guidolin, D.,
Filaferro, M., Marcellino, D., Fuxe,
K., et al. (2010). Differential sen-
sitivity of A2A and especially D2
receptor trafficking to cocaine com-
pared with lipid rafts in cotrans-
fected CHO cell lines. Novel actions
of cocaine independent of the DA
transporter. J. Mol. Neurosci. 41,
347–357.
Gimpl, G., Burger, K., and Fahrenholz,
F. (1997). Cholesterol as modulator
of receptor function. Biochemistry
36, 10959–10974.
Gimpl, G., and Fahrenholz, F. (2002).
Cholesterol as stabilizer of the oxy-
tocin receptor. Biochim. Biophys.
Acta 1564, 384–392.
Gimpl, G., Wiegand, V., Burger, K., and
Fahrenholz, F. (2002). Cholesterol
and steroid hormones: modulators
of oxytocin receptor function. Prog.
Brain Res. 139, 43–55.
Hadac, E. M., Dawson, E. S., Darrow, J.
W., Sugg, E. E., Lybrand, T. P., and
Miller, L. J. (2006). Novel benzodi-
azepine photoaffinity probe stereos-
electively labels a site deep within
the membrane-spanning domain of
the cholecystokinin receptor. J. Med.
Chem. 49, 850–863.
Hanson, M. A., Cherezov, V., Griffith,
M. T., Roth, C. B., Jaakola, V. P.,
Chien, E. Y., et al. (2008). A spe-
cific cholesterol binding site is estab-
lished by the 2.8 A structure of
the human beta2-adrenergic recep-
tor. Structure 16, 897–905.
Harikumar, K. G., Clain, J., Pinon,
D. I., Dong, M., and Miller, L. J.
(2005a). Distinct molecular mech-
anisms for agonist peptide binding
to types A and B cholecystokinin
receptors demonstrated using fluo-
rescence spectroscopy. J. Biol. Chem.
280, 1044–1050.
Harikumar, K. G., Puri, V., Singh, R.
D., Hanada, K., Pagano, R. E., and
Miller, L. J. (2005b). Differential
effects of modification of mem-
brane cholesterol and sphingolipids
on the conformation, function, and
trafficking of the G protein-coupled
cholecystokinin receptor. J. Biol.
Chem. 280, 2176–2185.
Harikumar, K. G., and Miller, L.
J. (2005). Fluorescence reso-
nance energy transfer analysis
of the antagonist- and partial
agonist-occupied states of the
cholecystokinin receptor. J. Biol.
Chem. 280, 18631–18635.
Harikumar, K. G., Pinon, D. I., and
Miller, L. J. (2006). Fluorescent indi-
cators distributed throughout the
pharmacophore of cholecystokinin
provide insights into distinct modes
of binding and activation of type
A and B cholecystokinin receptors.
J. Biol. Chem. 281, 27072–27080.
Harikumar, K. G., Pinon, D. I., Wessels,
W. S., Dawson, E. S., Lybrand, T.
P., Prendergast, F. G., et al. (2004).
Measurement of intermolecular
distances for the natural agonist
Peptide docked at the cholecys-
tokinin receptor expressed in situ
using fluorescence resonance energy
transfer. Mol. Pharmacol. 65, 28–35.
Harikumar, K. G., Pinon, D. I., Wessels,
W. S., Prendergast, F. G., and
Miller, L. J. (2002). Environment
and mobility of a series of fluores-
cent reporters at the amino termi-
nus of structurally related peptide
agonists and antagonists bound to
the cholecystokinin receptor. J. Biol.
Chem. 277, 18552–18560.
Harper, A. A., and Raper, H. S. (1943).
Pancreozymin, a stimulant of the
secretion of pancreatic enzymes
in extracts of the small intestine.
J. Physiol. 102, 115–125.
Herranz, R. (2003). Cholecystokinin
antagonists: pharmacological and
therapeutic potential. Med. Res. Rev.
23, 559–605.
Huang, P., Xu, W., Yoon, S. I., Chen,
C., Chong, P. L., and Liu-Chen,
L. Y. (2007). Cholesterol reduc-
tion by methyl-beta-cyclodextrin
attenuates the delta opioid receptor-
mediated signaling in neuronal cells
but enhances it in non-neuronal
cells. Biochem. Pharmacol. 73,
534–549.
Ipsen, J. H., Karlstrom, G.,
Mouritsen, O. G., Wennerstrom,
H., and Zuckermann, M. J.
(1987). Phase equilibria in the
phosphatidylcholine-cholesterol
system. Biochim. Biophys. Acta 905,
162–172.
Jafurulla, M., Tiwari, S., and
Chattopadhyay, A. (2011).
Identification of cholesterol recog-
nition amino acid consensus
(CRAC)motif in G-protein coupled
receptors. Biochem. Biophys. Res.
Commun. 404, 569–573.
Kalindjian, S. B., and McDonald, I. M.
(2007). Strategies for the design of
Frontiers in Endocrinology | Neuroendocrine Science October 2012 | Volume 3 | Article 123 | 8
Desai and Miller Cholesterol impact on cholecystokinin action
non-peptide CCK2 receptor agonist
and antagonist ligand. Curr. Top.
Med. Chem. 7, 1195–1204.
Kano, M., Shoda, J., Satoh, S.,
Kobayashi, M., Matsuzaki, Y.,
Abei, M., et al. (2002). Increased
expression of gallbladder chole-
cystokinin: a receptor in prairie
dogs fed a high-cholesterol diet
and its dissociation with decreased
contractility in response to chole-
cystokinin. J. Lab. Clin. Med. 139,
285–294.
Kerstens, P. J., Lamers, C. B., Jansen,
J. B., De Jong, A. J., Hessels, M.,
and Hafkenscheid, J. C. (1985).
Physiological plasma concentra-
tions of cholecystokinin stimulate
pancreatic enzyme secretion and
gallbladder contraction in man. Life
Sci. 36, 565–569.
Kissileff, H. R., Pi-Sunyer, F. X.,
Thornton, J., and Smith, G. P.
(1981). C-terminal octapeptide
of cholecystokinin decreases food
intake in man. Am. J. Clin. Nutr. 34,
154–160.
Kopin, A. S., Beinborn, M., Lee, Y. M.,
McBride, E. W., and Quinn, S. M.
(1994). The CCK-B/gastrin recep-
tor. Identification of amino acids
that determine nonpeptide antago-
nist affinity. Ann.N.Y. Acad. Sci. 713,
67–78.
Kopin, A. S., Lee, Y. M., McBride,
E. W., Miller, L. J., Lu, M., Lin,
H. Y., et al. (1992). Expression
cloning and characterization of the
canine parietal cell gastrin recep-
tor. Proc. Natl. Acad. Sci. U.S.A. 89,
3605–3609.
Kopin, A. S., McBride, E. W., Quinn,
S. M., Kolakowski, L. F. Jr., and
Beinborn, M. (1995). The role
of the cholecystokinin-B/gastrin
receptor transmembrane domains
in determining affinity for subtype-
selective ligands. J. Biol. Chem. 270,
5019–5023.
Ladines, C. A., Zeng, C., Asico, L.
D., Sun, X., Pocchiari, F., Semeraro,
C., et al. (2001). Impaired renal
D(1)-like and D(2)-like dopamine
receptor interaction in the spon-
taneously hypertensive rat. Am. J.
Physiol. Regul. Integr. Comp. Physiol.
281, R1071–R1078.
Lagane, B., Gaibelet, G., Meilhoc,
E., Masson, J. M., Cezanne, L.,
and Lopez, A. (2000). Role of
sterols in modulating the human
mu-opioid receptor function in
Saccharomyces cerevisiae. J. Biol.
Chem. 275, 33197–33200.
Lamorte, W. W., Brotschi, E. A., Scott,
T. E., and Williams, L. F. Jr.
(1985). Pigment gallstone forma-
tion in the cholesterol-fed guinea
pig. Hepatology 5, 21–27.
Lange, Y., and D’Alessandro, J. S.
(1977). Characterization of mech-
anisms for transfer of cholesterol
between human erythrocytes
and plasma. Biochemistry 16,
4339–4343.
Lee, A. G. (2004). How lipids affect the
activities of integral membrane pro-
teins. Biochim. Biophys. Acta 1666,
62–87.
Li, H., and Papadopoulos, V. (1998).
Peripheral-type benzodiazepine
receptor function in choles-
terol transport. Identification
of a putative cholesterol recog-
nition/interaction amino acid
sequence and consensus pattern.
Endocrinology 139, 4991–4997.
Meyer, B. H., Segura, J. M., Martinez,
K. L., Hovius, R., George, N.,
Johnsson, K., et al. (2006).
FRET imaging reveals that func-
tional neurokinin-1 receptors are
monomeric and reside in mem-
brane microdomains of live cells.
Proc. Natl. Acad. Sci. U.S.A. 103,
2138–2143.
Miao, L., Nielsen, M., Thewalt, J., Ipsen,
J. H., Bloom, M., Zuckermann, M.
J., et al. (2002). From lanosterol to
cholesterol: structural evolution and
differential effects on lipid bilayers.
Biophys. J. 82, 1429–1444.
Miller, L. J., and Gao, F. (2008).
Structural basis of cholecystokinin
receptor binding and regulation.
Pharmacol. Ther. 119, 83–95.
Miller, L. J., Holicky, E. L., Ulrich,
C. D., and Wieben, E. D. (1995).
Abnormal processing of the human
cholecystokinin receptor gene in
association with gallstones and
obesity. Gastroenterology 109,
1375–1380.
Miller, L. J., Jardine, I., Weissman,
E., Go, V. L., and Speicher, D.
(1984). Characterization of chole-
cystokinin from the human brain.
J. Neurochem. 43, 835–840.
Miller, L. J., and Lybrand, T. P. (2002).
Molecular basis of agonist binding
to the type A cholecystokinin recep-
tor. Pharmacol. Toxicol. 91, 282–285.
Mitchell, D. C., Straume, M., Miller,
J. L., and Litman, B. J. (1990).
Modulation of metarhodopsin for-
mation by cholesterol-induced
ordering of bilayer lipids.
Biochemistry 29, 9143–9149.
Monastyrskaya, K., Hostettler, A.,
Buergi, S., and Draeger, A. (2005).
The NK1 receptor localizes to the
plasma membrane microdomains,
and its activation is dependent on
lipid raft integrity. J. Biol. Chem.
280, 7135–7146.
Mouritsen, O. G., and Zuckermann, M.
J. (2004). What’s so special about
cholesterol? Lipids 39, 1101–1113.
Nardone, G., Ferber, I. A., andMiller, L.
J. (1995). The integrity of the chole-
cystokinin receptor gene in gallblad-
der disease and obesity. Hepatology
22, 1751–1753.
Nguyen, D. H., and Taub, D.
(2002a). Cholesterol is essential
for macrophage inflammatory
protein 1 beta binding and confor-
mational integrity of CC chemokine
receptor 5. Blood 99, 4298–4306.
Nguyen, D. H., and Taub, D. (2002b).
CXCR4 function requires mem-
brane cholesterol: implications for
HIV infection. J. Immunol. 168,
4121–4126.
Nguyen, D. H., and Taub, D. D. (2003).
Inhibition of chemokine receptor
function by membrane cholesterol
oxidation. Exp. Cell Res. 291, 36–45.
Nichols, J. W., and Pagano, R. E.
(1981). Kinetics of soluble lipid
monomer diffusion between vesi-
cles. Biochemistry 20, 2783–2789.
Niu, S. L., Mitchell, D. C., and Litman,
B. J. (2002).Manipulation of choles-
terol levels in rod disk membranes
by methyl-beta-cyclodextrin: effects
on receptor activation. J. Biol. Chem.
277, 20139–20145.
Noble, F. (2007). Pharmacology of
CCKRs and SAR studies of pep-
tidic analog ligands. Curr. Top. Med.
Chem. 7, 1173–1179.
Noble, F., and Roques, B. P. (1999).
CCK-B receptor: chemistry, molec-
ular biology, biochemistry and
pharmacology. Prog. Neurobiol. 58,
349–379.
Oddi, S., Dainese, E., Fezza, F., Lanuti,
M., Barcaroli, D., De Laurenzi,
V., et al. (2011). Functional
characterization of putative choles-
terol binding sequence (CRAC)
in human type-1 cannabinoid
receptor. J. Neurochem. 116,
858–865.
Ohvo-Rekila, H., Ramstedt, B.,
Leppimaki, P., and Slotte, J. P.
(2002). Cholesterol interactions
with phospholipids in membranes.
Prog. Lipid Res. 41, 66–97.
Ohyama, K., Yamano, Y., Sano, T.,
Nakagomi, Y., Wada, M., and
Inagami, T. (2002). Role of the
conserved DRY motif on G protein
activation of rat angiotensin II
receptor type 1A. Biochem. Biophys.
Res. Commun. 292, 362–367.
Okamoto, T., Schlegel, A., Scherer,
P. E., and Lisanti, M. P. (1998).
Caveolins, a family of scaffolding
proteins for organizing “preassem-
bled signaling complexes” at the
plasma membrane. J. Biol. Chem.
273, 5419–5422.
Ostrom, R. S., and Insel, P. A. (2004).
The evolving role of lipid rafts
and caveolae in G protein-coupled
receptor signaling: implications
for molecular pharmacology. Br.
J. Pharmacol. 143, 235–245.
Paila, Y. D., Tiwari, S., and
Chattopadhyay, A. (2009). Are
specific nonannular cholesterol
binding sites present in G-protein
coupled receptors? Biochim.
Biophys. Acta 1788, 295–302.
Pang, L., Graziano, M., and Wang,
S. (1999). Membrane cholesterol
modulates galanin-GalR2 interac-
tion. Biochemistry 38, 12003–12011.
Pike, L. J. (2003). Lipid rafts: bring-
ing order to chaos. J. Lipid Res. 44,
655–667.
Pontier, S. M., Percherancier, Y.,
Galandrin, S., Breit, A., Gales,
C., and Bouvier, M. (2008).
Cholesterol-dependent separation
of the beta2-adrenergic receptor
from its partners determines signal-
ing efficacy: insight into nanoscale
organization of signal transduction.
J. Biol. Chem. 283, 24659–24672.
Potter, R. M., Harikumar, K. G., Wu,
S. V., and Miller, L. J. (2012).
Differential sensitivity of types 1
and 2 cholecystokinin receptors to
membrane cholesterol. J. Lipid Res.
53, 137–148.
Proulx, C. D., Holleran, B. J., Boucard,
A. A., Escher, E., Guillemette, G.,
and Leduc, R. (2008). Mutational
analysis of the conserved Asp2.50
and ERYmotif reveals signaling bias
of the urotensin II receptor. Mol.
Pharmacol. 74, 552–561.
Pucadyil, T. J., and Chattopadhyay, A.
(2004). Cholesterol modulates lig-
and binding and G-protein coupling
to serotonin(1A) receptors from
bovine hippocampus. Biochim.
Biophys. Acta 1663, 188–200.
Pucadyil, T. J., and Chattopadhyay, A.
(2005). Cholesterol modulates the
antagonist-binding function of hip-
pocampal serotonin1A receptors.
Biochim. Biophys. Acta 1714, 35–42.
Rao, R. V., Roettger, B. F., Hadac, E.
M., and Miller, L. J. (1997). Roles
of cholecystokinin receptor phos-
phorylation in agonist-stimulated
desensitization of pancreatic acinar
cells and receptor-bearing Chinese
hamster ovary cholecystokinin
receptor cells. Mol. Pharmacol. 51,
185–192.
Rehfeld, J. F. (1978). Immunochemical
studies on cholecystokinin. II.
Distribution and molecular het-
erogeneity in the central nervous
system and small intestine of
man and hog. J. Biol. Chem. 253,
4022–4030.
Rehfeld, J. F., Sun, G., Christensen,
T., and Hillingso, J. G. (2001).
The predominant cholecystokinin
in human plasma and intestine
www.frontiersin.org October 2012 | Volume 3 | Article 123 | 9
Desai and Miller Cholesterol impact on cholecystokinin action
is cholecystokinin-33. J. Clin.
Endocrinol. Metab. 86, 251–258.
Reubi, J. C., Waser, B., Laderach,
U., Stettler, C., Friess, H., Halter,
F., et al. (1997). Localization of
cholecystokinin A and cholecys-
tokinin B-gastrin receptors in the
human stomach. Gastroenterology
112, 1197–1205.
Roettger, B. F., Pinon, D. I., Burghardt,
T. P., and Miller, L. J. (1999).
Regulation of lateral mobility and
cellular trafficking of the CCK
receptor by a partial agonist. Am. J.
Physiol. 276, C539–C547.
Roettger, B. F., Rentsch, R. U., Hadac, E.
M., Hellen, E. H., Burghardt, T. P.,
andMiller, L. J. (1995). Insulation of
a G protein-coupled receptor on the
plasmalemmal surface of the pan-
creatic acinar cell. J. Cell Biol. 130,
579–590.
Ruprecht, J. J., Mielke, T., Vogel, R.,
Villa, C., and Schertler, G. F. (2004).
Electron crystallography reveals
the structure of metarhodopsin I.
EMBO J. 23, 3609–3620.
Schmitz, F., Goke, M. N., Otte, J. M.,
Schrader, H., Reimann, B., Kruse,
M. L., et al. (2001). Cellular expres-
sion of CCK-A and CCK-B/gastrin
receptors in human gastric mucosa.
Regul. Pept. 102, 101–110.
Schroeder, F., Frolov, A. A., Murphy, E.
J., Atshaves, B. P., Jefferson, J. R.,
Pu, L., et al. (1996). Recent advances
in membrane cholesterol domain
dynamics and intracellular choles-
terol trafficking. Proc. Soc. Exp. Biol.
Med. 213, 150–177.
Shaw, A. S. (2006). Lipid rafts: now
you see them, now you don’t. Nat.
Immunol. 7, 1139–1142.
Silvente-Poirot, S., and Wank, S. A.
(1996). A segment of five amino
acids in the second extracellular
loop of the cholecystokinin-B recep-
tor is essential for selectivity of
the peptide agonist gastrin. J. Biol.
Chem. 271, 14698–14706.
Sjogren, B., Hamblin, M. W., and
Svenningsson, P. (2006). Cholesterol
depletion reduces serotonin bind-
ing and signaling via human
5-HT(7(a)) receptors. Eur. J.
Pharmacol. 552, 1–10.
Slotte, J. P., and Lundberg, B. (1983).
Transfer of [3H]cholesterol between
lipid vesicles and rat arterial smooth
muscle cells in vitro. Biochim.
Biophys. Acta 750, 434–439.
Smith, G. P., and Gibbs, J. (1985).
The satiety effect of cholecystokinin.
Recent progress and current prob-
lems. Ann. N.Y. Acad. Sci. 448,
417–423.
Von Schrenck, T., Ahrens, M.,
De Weerth, A., Bobrowski, C.,
Wolf, G., Jonas, L., et al. (2000).
CCKB/gastrin receptors mediate
changes in sodium and potassium
absorption in the isolated perfused
rat kidney. Kidney Int 58, 995–1003.
Xiao, Z. L., Chen, Q., Amaral, J.,
Biancani, P., Jensen, R. T., and
Behar, J. (1999). CCK receptor
dysfunction in muscle membranes
from human gallbladders with
cholesterol stones. Am. J. Physiol.
276, G1401–G1407.
Xu, W., Yoon, S. I., Huang, P., Wang, Y.,
Chen, C., Chong, P. L., et al. (2006).
Localization of the kappa opioid
receptor in lipid rafts. J. Pharmacol.
Exp. Ther. 317, 1295–1306.
Yu, P., Chen, Q., Biancani, P., and
Behar, J. (1996). Membrane choles-
terol alters gallbladder muscle con-
tractility in prairie dogs. Am. J.
Physiol. 271, G56–G61.
Yu, P., Chen, Q., Harnett, K. M.,
Amaral, J., Biancani, P., and Behar,
J. (1995). Direct G protein acti-
vation reverses impaired CCK sig-
naling in human gallbladders with
cholesterol stones. Am. J. Physiol.
269, G659–G665.
Yu, P., Yang, Z., Jones, J. E., Wang,
Z., Owens, S. A., Mueller, S. C.,
et al. (2004). D1 dopamine receptor
signaling involves caveolin-2 in
HEK-293 cells. Kidney Int. 66,
2167–2180.
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 04 August 2012; paper pend-
ing published: 23 August 2012; accepted:
01 October 2012; published online: 18
October 2012.
Citation: Desai AJ and Miller LJ (2012)
Sensitivity of cholecystokinin receptors
to membrane cholesterol content. Front.
Endocrin. 3:123. doi: 10.3389/fendo.
2012.00123
This article was submitted to Frontiers
in Neuroendocrine Science, a specialty of
Frontiers in Endocrinology.
Copyright © 2012 Desai and Miller.
This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and reproduc-
tion in other forums, provided the origi-
nal authors and source are credited and
subject to any copyright notices concern-
ing any third-party graphics etc.
Frontiers in Endocrinology | Neuroendocrine Science October 2012 | Volume 3 | Article 123 | 10
